creatine has been researched along with Clostridioides difficile Infection in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade." | 2.79 | Risk estimation for recurrent Clostridium difficile infection based on clinical factors. ( Collins, SH; D'Agostino, RB; Gorbach, S; Kean, Y; Pencina, KM, 2014) |
| "In conclusion, both leukocytosis and renal failure are useful predictors, although timing of measurement is important." | 1.38 | Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. ( Bauer, MP; Dale, AP; Fawley, WN; Gerding, DN; Gorbach, SL; Hensgens, MP; Kuijper, EJ; Miller, MA; Wilcox, MH, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Agostino, RB | 1 |
| Collins, SH | 1 |
| Pencina, KM | 1 |
| Kean, Y | 1 |
| Gorbach, S | 1 |
| Bauer, MP | 1 |
| Hensgens, MP | 1 |
| Miller, MA | 1 |
| Gerding, DN | 1 |
| Wilcox, MH | 1 |
| Dale, AP | 1 |
| Fawley, WN | 1 |
| Kuijper, EJ | 1 |
| Gorbach, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)[NCT00468728] | Phase 3 | 535 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea[NCT00314951] | Phase 3 | 629 participants (Actual) | Interventional | 2006-05-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of subjects with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00468728)
Timeframe: Study day 10 (+/- 2 days)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 86.7 |
| PAR-101/OPT-80 | 87.7 |
Achieving a cure response at end of treatment and not having a recurrence at any time up to the post-study visit. (NCT00468728)
Timeframe: End of Study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 63.3 |
| PAR-101/OPT-80 | 76.7 |
Percentage of subjects with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00468728)
Timeframe: Study days 11-40
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 27.0 |
| PAR-101/OPT-80 | 12.6 |
Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00314951)
Timeframe: Study day 10 (+/- 2 days)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 85.7 |
| Fidaxomicin | 88.2 |
Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40. (NCT00314951)
Timeframe: End of Study (Day 40)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 64.2 |
| Fidaxomicin | 74.4 |
Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00314951)
Timeframe: Study days 11-40
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 25.1 |
| Fidaxomicin | 15.7 |
1 trial available for creatine and Clostridioides difficile Infection
| Article | Year |
|---|---|
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
1 other study available for creatine and Clostridioides difficile Infection
| Article | Year |
|---|---|
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Confidence | 2012 |